

1/6

Pembrolizumab Light Chain

EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLIYLASYLESGVPARFSGSGSGTDFTLTISSL
EPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDYSLSSITLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:5).

Pembrolizumab Heavy Chain

QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSS
TTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWCGGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
FLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLK (SEQ ID NO:10).

FIG.1

2/6




FIG.2

3/6




FIG.3A




FIG.3B

4/6




FIG.4A




FIG.4B




FIG. 5




FIG. 6




FIG. 7

Abbreviations: AE=adverse event; ALK=Anaplastic lymphoma kinase; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; IV=intravenous; NSCLC=non-small cell lung cancer; PD-L1 TPS=programmed cell death ligand 1 tumor proportion score; Q3W= every 3 weeks; R=randomization; SC=subcutaneous; vs=versus